CNB-001 [CAS 1019110-87-2]

CNB-001 is a potent and orally active 5-lipoxygenase (5-LOX) inhibitor. CNB-001 can decreases 5-LOX expression and increase proteasome activity. CNB-001 can inhibit accumulation of soluble Amyloid-β and ubiquitinated aggregated proteins. CNB-001 can inhibit apoptosis, ROS production and stabilize mitochondrial membrane potential. CNB-001 can reduce insulin resistance and increase glucose uptake. CNB-001 also exhibits anti-ischemic, anti-inflammatory effects. CNB-001 can be used for the researches of inflammation, neurological and metabolic disease, such as Alzheimer's disease, stroke and diabetes[1][2][3][4].

[1019110-87-2]

C27H24N2O4

440.49

OC1=CC=C(C=C1OC)/C=C/C2=NN(C3=CC=CC=C3)C(/C=C/C4=CC(OC)=C(O)C=C4)=C2

Amyloid-β; Apoptosis; Lipoxygenase; Reactive Oxygen Species (ROS)

15-LOX;5-LOX

90.7

10 mM in DMSO

4°C (Powder, sealed storage, away from moisture)

Room Temperature